Invention Grant
- Patent Title: Inhibitors of neuroligin 4-neurexin 1-beta protein-protein interaction for treatment of liver disorders
-
Application No.: US17388218Application Date: 2021-07-29
-
Publication No.: US11718666B2Publication Date: 2023-08-08
- Inventor: Rifaat Safadi
- Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
- Applicant Address: IL Jerusalem
- Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
- Current Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
- Current Assignee Address: IL Jerusalem
- Agency: Raphael Bellum PLLC
- The original application number of the division: US15562602
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K38/16 ; A61K38/17 ; A61P1/16 ; A61K39/00
Abstract:
Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
Public/Granted literature
- US20220010009A1 INHIBITORS OF NEUROLIGIN 4-NEUREXIN 1-BETA PROTEIN-PROTEIN INTERACTION FOR TREATMENT OF LIVER DISORDERS Public/Granted day:2022-01-13
Information query
